Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion

Thu Jan 31, 2013 10:17am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130131:nPnNY51731












KANSAS CITY, Kan.  and  BOSTON, Jan. 31, 2013 /PRNewswire/ -- Aratana
Therapeutics, a biopharmaceutical company developing innovative medicines for
cats and dogs (companion animals), today announced it has closed on a  $12
million  Series C financing.  Proceeds will fund the continued expansion of
Aratana's pipeline of companion animal therapeutic products.  Existing Aratana
investors, as well as new investors, participated in the over-subscribed
financing.

"Aratana is on a strong growth trajectory," stated  Steven St. Peter, M.D.,
President and Chief Executive Officer of Aratana Therapeutics.  "As we focus on
advancing our current development pipeline toward approval and
commercialization, we will use funds from this round to add to our portfolio of
animal health products, ensuring Aratana's future growth.  We thank our
investors for their support and enthusiasm and together we look forward to
continued successful execution from our expert senior development and commercial
team."

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high
quality new medicines that address significant therapeutic needs for cats and
dogs (companion animals).  Aratana licenses and develops proprietary,
patent-protected compounds acquired from human pharmaceutical and biotechnology
companies and then develops strategies to maximize the value of the programs for
the animal health market.  For more information, please visit 
www.aratanatherapeutics.com.

For Investors & Media:
Joshua Drumm, Ph.D. /  Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
amielach@tiberend.com

SOURCE  Aratana Therapeutics

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.